<DOC>
	<DOC>NCT01614041</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.</brief_summary>
	<brief_title>Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Tandospirone</mesh_term>
	<criteria>1865 years old Male or female Diagnosed with GAD according to DSMIV HAMA score≥17 Provide with written informed consent Agree to be washedout for two weeks if receiving SSRI, SNRI or NASA. Serious suicidal tendency The score of the sixth item of HAMA ≥3 The score of HAMD ≥21 Pregnant or lactating women History of allergic or hypersensitivity to tandospirone Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease Secondary anxiety disorders Drug or alcohol dependence within 1 year Patients currently taking benzodiazepine drugs Drivers and dangerous machine operators Participated in other clinical studies in the last 30 days Patients with clinically significant ECG or laboratory abnormalities Patients with a history of epilepsy Patients with abnormal TSH concentration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
</DOC>